Acromegaly is a rare and serious condition related to the
hypersecretion of growth hormone by the pituitary gland,
generally of tumoral origin. This causes an uncontrolled growth
of organs, debilitating symptoms and a shorter life expectancy.
Pharmacotherapy with somatostatin analogs is one of the treatment options, a life-long treatment with a few and mild side effects. Novartis’ Sandostatin® (octreotide) is the market leader and which efficacy is clearly established for treating acromegaly. The yearly treatment with the long-acting release (LAR) formulation of the product, which consists of intramuscular injections every 4 weeks, is costly. Difficult reconstitution prior to injection is also an issue.
The safety and efficacy of the product are currently under study.
Ambrilia’s C2L is available for licensing or divestment. For more information, please contact:
Richard La Rue, LL.L, D.D.N.
Interim President & CEO
Tel.: (514) 751-3002 ex. 269
e-mail: rlarue@ambrilia.com
Sandostatin®LAR is a registered trademark of Novartis Pharmaceuticals
Improved formulation of Sandostatin®LAR
Acromegaly and rare gastrointestinal tumors
Phase III
Patented delivery system technology
Archimedes Pharma: U.K.
Gerolymatos: Greece, Turkey and other countries
Kwidza Pharma: Austria
Omega: Canada, Egypt
Pharmis: Portugal, Brazil
Shin Poong: Korea
Genepharm Limited: Australia & New Zealand